Addition of the MUC-1 vaccine tecemotide to neoadjuvant systemic therapy for patients with early breast cancer: Survival results from the prospective randomized ABCSG 34 trial.Christian F. Singer, Michael Gnant, Rupert Bartsch et al.|Journal of Clinical Oncology|2024Cited by 6
Abstract PS3-03: Vaccination with MUC-1-targeting tecemotide improves Survival of patients receiving neo-adjuvant chemotherapy for early breast cancer: Results from the Prospective Randomized ABCSG 34 TrialChristian F. Singer, Michael Gnant, Dominik Hlauschek et al.|Clinical Cancer Research|2025Cited by 1